Historical record - last NADAC effective date: 5/20/2020
Product Information
CLOTRIMAZOLE 1% TOPICAL CREAM is a generic product labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., priced at $0.3439 per GM under NDC 00168013346. Its NADAC has been published 339 times since Nov 28, 2013.
FDA first approved this application on Sep 2, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/g
NDC
00168013346
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
5/20/2020
Active Ingredients
CLOTRIMAZOLEApproval Type
Generic (ANDA)
FDA Application
ANDA078338FDA Approved
9/2/2008
TE Code
AB
On Market Since
9/2/2008
Pharmacological Classes
Price Statistics
The NADAC for CLOTRIMAZOLE 1% TOPICAL CREAM has been published 339 times since Nov 28, 2013, and over the history we have for it it has declined 47.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3439 per GM |
|---|---|
| All-time high | $0.6987 (Jun 11, 2014) |
| All-time low | $0.3283 (Jan 23, 2019) |
| Median price | $0.5624 |
| Average price | $0.5226 |
| Largest weekly change | +23.4% (Feb 20, 2019) |
| Weeks tracked | 339 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-47.0%
Last surveyed May 20, 2020 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 43% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
clotrimazole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Azole Antifungal class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLOTRIMAZOLE 1% TOPICAL CREAM?
The current National Average Drug Acquisition Cost (NADAC) for CLOTRIMAZOLE 1% TOPICAL CREAM, manufactured by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., is $0.3439 per GM (NDC 00168013346), effective May 20, 2020.
How has the price of CLOTRIMAZOLE 1% TOPICAL CREAM changed over time?
Over the history we have for it, the NADAC for CLOTRIMAZOLE 1% TOPICAL CREAM has declined 47.0%. It has been tracked across 339 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CLOTRIMAZOLE 1% TOPICAL CREAM?
Since Nov 28, 2013, the NADAC for CLOTRIMAZOLE 1% TOPICAL CREAM has ranged from a low of $0.3283 (Jan 23, 2019) to a high of $0.6987 (Jun 11, 2014), with a median of $0.5624 per GM.
Are there cheaper alternatives to CLOTRIMAZOLE 1% TOPICAL CREAM?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLOTRIMAZOLE 1% TOPICAL CREAM, is $0.1945 per GM — about 43% below CLOTRIMAZOLE 1% TOPICAL CREAM.
Who manufactures CLOTRIMAZOLE 1% TOPICAL CREAM?
CLOTRIMAZOLE 1% TOPICAL CREAM (NDC 00168013346) is labeled by E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., and CMS classifies it as a generic product.